Giovanni Della Cioppa

6.4k total citations · 2 hit papers
55 papers, 5.0k citations indexed

About

Giovanni Della Cioppa is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, Giovanni Della Cioppa has authored 55 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Physiology, 25 papers in Pulmonary and Respiratory Medicine and 18 papers in Epidemiology. Recurrent topics in Giovanni Della Cioppa's work include Asthma and respiratory diseases (31 papers), Influenza Virus Research Studies (18 papers) and Respiratory and Cough-Related Research (15 papers). Giovanni Della Cioppa is often cited by papers focused on Asthma and respiratory diseases (31 papers), Influenza Virus Research Studies (18 papers) and Respiratory and Cough-Related Research (15 papers). Giovanni Della Cioppa collaborates with scholars based in United States, Switzerland and United Kingdom. Giovanni Della Cioppa's co-authors include Niroo Gupta, J. Thirlwell, Andre van As, Angel FowlerTaylor, William W. Busse, Bobby Q. Lanier, Jonathan Corren, Roland Buhl, H. Fox and M. Solèr and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, American Journal of Epidemiology and CHEST Journal.

In The Last Decade

Giovanni Della Cioppa

54 papers receiving 4.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma

2001 978 citations Giovanni Della Cioppa et al. Journal of Allergy and Clinical Immunology profile →
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

2001 647 citations M. Solèr, Jonathan Matz et al. European Respiratory Journal profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Giovanni Della Cioppa United States	30	3.6k	2.8k	1.6k	860	839	55	5.0k
Henk M. Jansen Netherlands	36	1.2k 0.3×	1.4k 0.5×	660 0.4×	1.0k 1.2×	1.1k 1.3×	94	3.9k
Rohit Katial United States	29	1.8k 0.5×	1.3k 0.5×	740 0.5×	263 0.3×	706 0.8×	121	3.0k
Christian Vogelberg Germany	28	1.3k 0.4×	782 0.3×	759 0.5×	296 0.3×	323 0.4×	147	2.5k
Dennis K. Ledford United States	31	1.4k 0.4×	692 0.3×	2.0k 1.2×	234 0.3×	464 0.6×	116	3.9k
Vasile Laza‐Stanca United Kingdom	21	1.9k 0.5×	1.2k 0.4×	257 0.2×	1.6k 1.8×	1.8k 2.1×	29	3.7k
Richard Loh Australia	26	960 0.3×	322 0.1×	1.1k 0.7×	446 0.5×	1.0k 1.2×	72	2.8k
Mark Schuyler United States	25	869 0.2×	1.5k 0.5×	224 0.1×	254 0.3×	565 0.7×	68	2.5k
Mohamed H. Shamji United Kingdom	42	3.5k 1.0×	424 0.2×	4.4k 2.7×	93 0.1×	965 1.2×	153	5.8k
Peter Oluf Schiøtz Denmark	31	515 0.1×	754 0.3×	491 0.3×	243 0.3×	654 0.8×	100	2.3k
Madelyn Berger United States	27	512 0.1×	1.3k 0.5×	327 0.2×	445 0.5×	1.3k 1.5×	53	3.3k

Countries citing papers authored by Giovanni Della Cioppa

Since Specialization

Citations

This map shows the geographic impact of Giovanni Della Cioppa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Giovanni Della Cioppa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Giovanni Della Cioppa more than expected).

Fields of papers citing papers by Giovanni Della Cioppa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Giovanni Della Cioppa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Giovanni Della Cioppa. The network helps show where Giovanni Della Cioppa may publish in the future.

Co-authorship network of co-authors of Giovanni Della Cioppa

This figure shows the co-authorship network connecting the top 25 collaborators of Giovanni Della Cioppa. A scholar is included among the top collaborators of Giovanni Della Cioppa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Giovanni Della Cioppa. Giovanni Della Cioppa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hampson, Lisa V., Björn Bornkamp, Björn Holzhauer, et al.. (2021). Improving the assessment of the probability of success in late stage drug development. Pharmaceutical Statistics. 21(2). 439–459. 12 indexed citations

Knuf, Markus, Geert Leroux‐Roels, H. C. Rümke, et al.. (2015). Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children. Human Vaccines & Immunotherapeutics. 11(2). 358–376. 11 indexed citations

Knuf, Markus, Geert Leroux‐Roels, H. C. Rümke, et al.. (2014). Immunogenicity and Tolerability of an MF59-adjuvanted, Egg-derived, A/H1N1 Pandemic Influenza Vaccine in Children 6–35 Months of Age. The Pediatric Infectious Disease Journal. 33(12). e320–e329. 10 indexed citations

Cioppa, Giovanni Della, Uwe Nicolay, Kelly Lindert, et al.. (2014). A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration. Human Vaccines & Immunotherapeutics. 10(6). 1701–1710. 26 indexed citations

Cioppa, Giovanni Della, Uwe Nicolay, Kelly Lindert, et al.. (2012). Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59^®adjuvant. Human Vaccines & Immunotherapeutics. 8(2). 216–227. 30 indexed citations

Cioppa, Giovanni Della, Timo Vesikari, Étienne Sokal, Kelly Lindert, & Uwe Nicolay. (2011). Trivalent and quadrivalent MF59®-adjuvanted influenza vaccine in young children: A dose- and schedule-finding study. Vaccine. 29(47). 8696–8704. 34 indexed citations

Arguedas, Adriano, Carolina Soley, Arturo Abdelnour, et al.. (2011). Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Human Vaccines. 7(1). 58–66. 34 indexed citations

Black, Steven, Uwe Nicolay, Timo Vesikari, et al.. (2011). Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children. The Pediatric Infectious Disease Journal. 30(12). 1081–1085. 272 indexed citations

Black, Steven, Giovanni Della Cioppa, Anne Malfroot, et al.. (2010). Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: An integrated analysis. Vaccine. 28(45). 7331–7336. 35 indexed citations

10.

Pellegrini, Michele, Uwe Nicolay, Kelly Lindert, Nicola Groth, & Giovanni Della Cioppa. (2009). MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database. Vaccine. 27(49). 6959–6965. 139 indexed citations

11.

Bronsky, Edwin A., Jay Grossman, Paul Gallo, et al.. (2004). Inspiratory flow rates and volumes with the Aerolizer dry powder inhaler in asthmatic children and adults. Current Medical Research and Opinion. 20(2). 131–137. 32 indexed citations

12.

Joos, Guy, Walter Vincken, Renaud Louis, et al.. (2003). Dual tachykinin NK₁/NK₂antagonist DNK333 inhibits neurokinin A‐induced bronchoconstriction in asthma patients. European Respiratory Journal. 23(1). 76–81. 49 indexed citations

13.

Bronsky, Edwin A., et al.. (2002). Formoterol provides long-lasting protection against exercise-induced bronchospasm. Annals of Allergy Asthma & Immunology. 89(4). 407–412. 21 indexed citations

14.

Buhl, Roland, M. Solèr, Jonathan Matz, et al.. (2002). Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. European Respiratory Journal. 20(1). 73–78. 162 indexed citations

15.

Dahl, Ronald, Dariusz Nowak, В Е Ноников, et al.. (2001). Inhaled Formoterol Dry Powder Versus Ipratropium Bromide in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine. 164(5). 778–784. 275 indexed citations

16.

Bensch, George, et al.. (2001). A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Annals of Allergy Asthma & Immunology. 86(1). 19–27. 56 indexed citations

17.

FitzGerald, J. Mark, et al.. (1999). Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. Journal of Allergy and Clinical Immunology. 103(3). 427–435. 62 indexed citations

18.

Lecaillon, J. B., et al.. (1999). Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of Foradil dry powder Inhalation via aerolizer TM. European Journal of Clinical Pharmacology. 55(2). 131–138. 75 indexed citations

19.

Burgess, Carl, et al.. (1998). The extrapulmonary effects of increasing doses of formoterol in patients with asthma. European Journal of Clinical Pharmacology. 54(2). 141–147. 43 indexed citations

20.

Atkins, Christopher J., A. Zieliński, Alice Klinkhoff, et al.. (1992). An electronic method for measuring joint tenderness in rheumatoid arthritis. Arthritis & Rheumatism. 35(4). 407–410. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact